RCEL

#3271
Avita Medical, Inc. - Common Stock
10.3 2 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
10.32
10.32
Jahresspanne
3.22
10.77
Tagesänderung
-2.55%
Monatliche Änderung
+123.86%
6 month change
+109.76%
Jahresänderung
+128.82%
Vorheriger Schlusskurs
10.5 9
Open
10.3 2
Tief
10.3 2
Hoch
10.3 2
Volumen
25
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
AVITA Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
AVITA Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
AVITA Medical, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
AVITA Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
AVITA Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
AVITA Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
AVITA Medical, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
AVITA Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
AVITA Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
AVITA Medical, Inc. current report, Q1 FY2026
8-K

AVITA Medical, Inc. current report, Q2 FY2025

Full document

AVITA Medical, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by AVITA Medical, Inc. on June 4, 2025. The meeting was conducted via remote webcast. The filing details the outcomes of shareholder votes regarding director elections, auditor ratification, equity compensation plans, and executive officer compensation.

Key Financial Metrics

The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and equity plan approvals.

Material Changes and Corporate Actions

  • Equity Plan Amendment: Stockholders approved the 2020 Omnibus Incentive Plan Amended and Restated, increasing the number of shares available for issuance by 2,500,000. The total shares issuable under the plan are now 6,750,000.
  • Director Elections: All seven nominees were elected to the Board of Directors. James Corbett received the highest number of "For" votes (9,972,296), while Lou Panaccio received the lowest (8,556,636).
  • Equity Grants:
    • Non-Executive Directors: Approved grants of 10,022 restricted stock units and 4,295 stock options to each of the six non-executive directors.
    • CEO: Approved a grant of options to acquire 520,000 shares of common stock to Chief Executive Officer James Corbett.
  • Auditor Ratification: Grant Thornton LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.

Guidance, Outlook, and Risks

The filing does not contain management commentary on future guidance, outlook, or specific risk factors. The document serves as a record of shareholder voting results and the approval of the amended incentive plan.

Investor Verification Checklist

  • Verify the full terms of the 2020 Omnibus Incentive Plan Amended and Restated in Annexure A of the Schedule 14A Proxy Statement filed on April 22, 2025.
  • Review the specific vesting schedules and exercise prices for the 520,000 CEO options and the director equity grants in the Proxy Statement.
  • Confirm the total number of shares outstanding post-approval to assess potential dilution from the increased 6,750,000 share pool.
  • Monitor the company's upcoming financial reports for the impact of these equity grants on future earnings per share.

Nachrichten